348 related articles for article (PubMed ID: 38102383)
1. Pharmacological reactivation of p53 in the era of precision anticancer medicine.
Tuval A; Strandgren C; Heldin A; Palomar-Siles M; Wiman KG
Nat Rev Clin Oncol; 2024 Feb; 21(2):106-120. PubMed ID: 38102383
[TBL] [Abstract][Full Text] [Related]
2. Small-molecule correctors and stabilizers to target p53.
Fallatah MMJ; Law FV; Chow WA; Kaiser P
Trends Pharmacol Sci; 2023 May; 44(5):274-289. PubMed ID: 36964053
[TBL] [Abstract][Full Text] [Related]
3. Translating p53-based therapies for cancer into the clinic.
Peuget S; Zhou X; Selivanova G
Nat Rev Cancer; 2024 Mar; 24(3):192-215. PubMed ID: 38287107
[TBL] [Abstract][Full Text] [Related]
4. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
5. CDK9 inhibitors reactivate p53 by downregulating iASPP.
Wu J; Liang Y; Tan Y; Tang Y; Song H; Wang Z; Li Y; Lu M
Cell Signal; 2020 Mar; 67():109508. PubMed ID: 31866490
[TBL] [Abstract][Full Text] [Related]
6. Targeting p53 for the treatment of cancer.
Duffy MJ; Synnott NC; O'Grady S; Crown J
Semin Cancer Biol; 2022 Feb; 79():58-67. PubMed ID: 32741700
[TBL] [Abstract][Full Text] [Related]
7. BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models.
Hao X; Bahia RK; Cseh O; Bozek DA; Blake S; Rinnenthal J; Weyer-Czernilofsky U; Rudolph D; Artee Luchman H
Neuro Oncol; 2023 May; 25(5):913-926. PubMed ID: 36521007
[TBL] [Abstract][Full Text] [Related]
8. Targeting mutant p53 for efficient cancer therapy.
Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
[TBL] [Abstract][Full Text] [Related]
9. p53 as a target for the treatment of cancer.
Duffy MJ; Synnott NC; McGowan PM; Crown J; O'Connor D; Gallagher WM
Cancer Treat Rev; 2014 Dec; 40(10):1153-60. PubMed ID: 25455730
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological reactivation of p53 as a strategy to treat cancer.
Zawacka-Pankau J; Selivanova G
J Intern Med; 2015 Feb; 277(2):248-259. PubMed ID: 25495071
[TBL] [Abstract][Full Text] [Related]
11. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.
Buolamwini JK; Addo J; Kamath S; Patil S; Mason D; Ores M
Curr Cancer Drug Targets; 2005 Feb; 5(1):57-68. PubMed ID: 15720190
[TBL] [Abstract][Full Text] [Related]
12. TP53 and MDM2 genetic alterations in non-small cell lung cancer: Evaluating their prognostic and predictive value.
Deben C; Deschoolmeester V; Lardon F; Rolfo C; Pauwels P
Crit Rev Oncol Hematol; 2016 Mar; 99():63-73. PubMed ID: 26689115
[TBL] [Abstract][Full Text] [Related]
13. Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed.
Zanjirband M; Rahgozar S
Curr Drug Targets; 2019; 20(11):1091-1111. PubMed ID: 30947669
[TBL] [Abstract][Full Text] [Related]
14. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
Merkel O; Taylor N; Prutsch N; Staber PB; Moriggl R; Turner SD; Kenner L
Mutat Res Rev Mutat Res; 2017 Jul; 773():1-13. PubMed ID: 28927521
[TBL] [Abstract][Full Text] [Related]
15. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
[TBL] [Abstract][Full Text] [Related]
16. [NEGATIVE REGULATORS OF TUMOR SUPPRESSOR P53 IN THE CONTEXT OF ANTICANCER THERAPY].
Shuvalov OY; Fedorova OA; Petukhov AV; Daks AA; Vasilieva EA; Grigorieva TA; Ivanov GS; Barlev NA
Tsitologiia; 2015; 57(12):847-54. PubMed ID: 26995961
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of p53 inhibitors: progress, challenges and perspectives.
Sanz G; Singh M; Peuget S; Selivanova G
J Mol Cell Biol; 2019 Jul; 11(7):586-599. PubMed ID: 31310659
[TBL] [Abstract][Full Text] [Related]
19. Modeling the Etiology of p53-mutated Cancer Cells.
Perez RE; Shen H; Duan L; Kim RH; Kim T; Park NH; Maki CG
J Biol Chem; 2016 May; 291(19):10131-47. PubMed ID: 27022024
[TBL] [Abstract][Full Text] [Related]
20. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]